SC
PHVS icon

Stempoint Capital’s Pharvaris PHVS Stock Holding History

Stempoint Capital’s Portfolio PHVS Stock Details PHVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.8M Sell
80,907
-5,730
-7% -$173K 0.48% 54
2026
Q1 		$2.45M Buy
86,637
+28,248
+48% +$754K 0.47% 49
2025
Q4 		$1.62M Buy
+58,389
New +$1.41M 0.28% 61

Other funds holding PHVS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
EFM
EQT Fund Management Luxembourg $863M AUM 26.03% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Stempoint Capital's PHVS Position: Q2 2026 in Review

Stempoint Capital reduced its Pharvaris (PHVS) stake by 6.6% in Q2 2026, selling an estimated $173K and leaving 80,907 shares worth $2.8M. The position accounts for 0.48% of the portfolio, ranked #54.

Stempoint Capital first reported a position in PHVS in Q4 2025 and has held it in 3 quarters since. 125 funds tracked by Wall St. Rank hold PHVS as of Q2 2026.

  • Stempoint Capital held 80,907 shares of Pharvaris worth $2.8M as of Q2 2026.
  • Stempoint Capital sold 5,730 Pharvaris shares in Q2 2026, an estimated $173K.
  • Pharvaris made up 0.48% of Stempoint Capital's portfolio in Q2 2026, its #54 holding.
  • Stempoint Capital first reported a position in Pharvaris in Q4 2025 and has held it in 3 quarters since.
  • 125 funds tracked by Wall St. Rank held Pharvaris as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.